Past Event

12th Biosimilars Congregation 2018

27–28 February 2018
London, United Kingdom

12th Biosimilars Congregation 2018

“Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars”

27th & 28th February 2018, Holiday Inn, Kensington High Street, London, UK

12th Biosimilars Congregation 2018 will provide insight into the current state of play in the EU and stimulate debate, in a multi-stakeholder setting, on the vital role of biosimilar medicines in the sustainability of healthcare systems. Beyond a comprehensive outlook of key European market access policies,  our speakers will outline the key recent developments in regulatory science and regulatory policy in the EU and other international jurisdictions. Special emphasis will be placed on strengthening the link between regulators and medical communities as an essential basis for greater understanding and acceptance of biosimilar medicines.


         NIRAJ CHHAYA, Senior Risk Management Physician of Biosimilar Compounds, Boehringer Ingelheim

         THOMAS SACHNIK, Senior Manager Strategic Associate to the President & CEO Generics Europe, Teva Pharmaceuticals

         SUE NAEYAERT, Global Head Pricing, Market Access, Government Affairs and Policy Biosimilars, Fresenius Kabi SwissBioSim

         CHRISTIAN AGBOTON, Sr Global Brand Medical Director - Global Medical Affairs, Takeda

         KAUSTUBH BERDE, Vice President - International Business : Emerging Markets, Wockhardt

         CORNELIA ULM, VP Regulatory Affairs Biosimilars, Biotec Regulatory Consulting GmbH (former Fresenius Kabi SwissBioSim GmbH)

         HANMANT BARKATE, Vice President & Head Medical Services, Glenmark

         ANNA AILLERIE, Director, Commercial Biosimilars EMEA, Lupin

         LIZ POLLITT, Director, BPCRCS

         FREDRIK SUNDBERG, Director Strategic Customer Relations, GE Healthcare

         BER OOMEN, Expert Member Health Care Professionals, European Medicines Agency

         MAARTEN VAN BAELEN, Market Access Director, Medicines for Europe

         LOUIS BOON, CSO, Bioceros

         PETER JORGENSEN, CEO, Danish Generic and Biosimilar Medicines Industry Association (IGL)

         ANDREAS HERRMANN, CEO, ValeriusBio

         VLADIMIR ZAH, CEO, ZRx Outcomes Research (Canada)

         ROBERT A. JOHNSTONE, Board Member, International Alliance of Patients Organisations

         STEINAR MADSEN, Medical Director, Norwegian Medicines Agency

         OMAR ALI, Visiting Lecturer, University of Portsmouth & Former Adviser, NICE

         FEDERICO POLLANO, Director Contract Manufacturing and BD, Polpharma Biologics

         ALEX KUDRIN, Independent Consultant and clinical expert

         DIVYA CHADHA MANEK, Head of BD (Commercial), NHS - NIHR Clinical Research Network

         PAUL CALVO, Director, Sterne, Kessler, Goldstein & Fox (USA)

         AIDAN FRY, Editor, Generics Bulletin

         SANDY EISEN, Chief Medical Officer, Frontline Pharma Consulting

         ANNA FORSYTHE, Managing Partner, Purple Squirrel Economics (USA)

         MARIE MANLEY, Partner, Head of the Regulatory Practice, Bristows

         JACQUELINE MULRYNE, Counsel, Arnold & Porter


 CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:

Biopharmaceuticals/ Biotherapeutics, Follow on Biologics/Follow on Proteins/Biosimilars, Biologics/Biotechnology/ Biogenerics, Legal Affairs , Intellectual Property, Health Economics, Pricing and Reimbursement, Clinical Immunology, Principal Scientist, Chief Scientific Officer, Process Control and Analytical Technologies, Analytical Characterisation, Regulatory Compliance, Pharmacovigilance, Drug Safety & Risk Management, Quality Affairs/ Quality Control, New Product Development, Process Science, Portfolio Management, Research & Development, Business Development, Business Operations, Scientific Affairs, Commercial Affairs, Marketing.


You can simply share your interest and queries to –Email:  TEL: 44 2036120886

         Introductory Offer: 3 Delegate Places for the Price Of 2 (Huge saving of �750 - Limited seats left)

         Super Early Discount (Until 17th December 2017): (�750 VAT per delegate)

         Standard Registration (From 18th December 2017):: Conference Delegate Pass (�1150 VAT per delegate

         Conference Sponsor, Exhibition Stalls & a paid Speaker Slots are also available.


Join this event which provides an important platform for Biosimilars stakeholders to discuss and share best practices in furthering Biosimilars development.

Related Events